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ABSTRACT  
Objective: To evaluate the effectiveness of nurse-led telephone health coaching to 
encourage self-management in a primary care population with mild symptoms of COPD.  
Design: Pragmatic, multi-centre randomised controlled trial.   
Setting: 71 general practices in four areas of England.  
Participants: 577 people, with MRC dyspnoea grade 1 or 2, recruited from primary care 
COPD registers with spirometry confirmed diagnosis, were randomised to the intervention 
(n=289) or usual care (n=288).  
Interventions: Nurse-delivered telephone health coaching intervention, underpinned by 
Social Cognitive Theory, promoting: accessing smoking cessation services, increasing 
physical activity, medication management and action planning (4 sessions over 11 weeks; 
postal information at weeks 16 and 24). Nurses received two days of training. The usual care 
group received a leaflet about COPD.  
Main outcome measures: The primary outcome was health related quality of life at 12 
months using the short version of the St Georges Respiratory Questionnaire (SGRQ-C).  
Results: The intervention was delivered with good fidelity: 86% of scheduled calls were 
delivered; 75% of participants received all four calls. 92% participants were followed-up at 
six months and 89% at 12 months. There was no difference in SGRQ-C total score at 12 
months (mean difference -1.3, 95%CI -3.6 to 0.9; p=0.2). Compared to usual care 
participants, at six months follow-up, the intervention group reported significantly greater 
physical activity, more had received a care plan (44% v 30%), rescue packs of antibiotics 
(37% v 29%) and inhaler technique check (68% v 55%). There were no differences in other 
secondary outcomes (dyspnoea, smoking cessation, anxiety, depression, self-efficacy, 
objectively measured physical activity). 
  
Conclusions 
A novel telephone health coaching intervention to promote behaviour change in primary care 
patients with mild symptoms of dyspnoea did lead to changes in self-management activities, 
but did not improve health related quality of life. 
Trial registration  
Current controlled trials ISRCTN 06710391 
Keywords  
COPD, self-management, physical activity, randomised controlled trial, health coaching,     
  
BACKGROUND  
Chronic diseases, such as chronic obstructive pulmonary disease (COPD), are a major 
cause of death and disability in high income countries and of rising importance in low and 
middle income countries.[1] Owing to their high prevalence and chronicity, current 
international policy focuses on the need to support patients to self-manage their 
conditions.[2] Most interventions designed to support self-management have been targeted 
at people with more severe disease who are likely to be motivated to change behaviour, and 
where there is the most opportunity for symptomatic improvement. However, more recent 
efforts have aimed to prevent onset or slow progression early in the disease course, in order 
to reduce the burden and costs of treating more advanced disease later. This prevention 
paradigm has only recently been adopted in COPD, with calls for interventions to reduce risk 
in people with early disease.[3]    
The growing number of people at risk of developing long-term conditions and the high 
prevalence of early disease, means an accessible and low resource approach needs to be 
taken to support self-management. One such approach is to use interactive telephone health 
coaching, with the coach and patient working together to identify barriers to behaviour 
change and finding ways to overcome them. Key techniques include modelling behaviour, 
goal setting and empowering the patient to improve their health status.[4] Telephone health 
coaching has shown potential benefits on self-efficacy, health behaviour and health status in 
a rapid review of trials in long-term conditions.[5] 
COPD is a common respiratory condition with an estimated 65 million people worldwide with 
moderate or severe disease;[1] like most chronic diseases, it causes a significant burden on 
health services and society and is a leading cause of death in most countries.[6, 7] 
Interventions to support self-management interventions in people with COPD have been 
shown to be effective in improving health related quality of life and in reducing hospital 
admissions among COPD patients,[8, 9] but trials have largely recruited people from 
  
secondary care and excluded those with mild disease.[9] However, people with mild 
dyspnoea represent 38-54% of diagnosed patients in primary care[10, 11] and with case-
finding initiatives this is likely to increase.[12]  
Many components of self-management interventions could promote better health and 
prevent disease progression in the early stages of COPD. Smoking is a major cause of 
COPD, and smoking cessation has been shown to be beneficial in maintaining better lung 
function and in slowing disease progression across all severity levels.[13, 14] Reduced 
physical activity level is an independent risk factor for exacerbations, hospitalisation and 
mortality among those with COPD[15, 16] and occurs even in the early stages of 
disease.[17] Inhaler treatments have well established efficacy in reducing exacerbations and 
admissions amongst patients with moderate and severe lung function, and growing evidence 
of effectiveness in improving clinical outcomes and reducing decline in lung function among 
people with more mild impairment.[18, 19] Any intervention that improves medication 
adherence and inhaler technique, which is frequently poor,[20] is thus likely to improve 
outcomes for patients. Sixty percent of primary care COPD patients report exacerbations of 
their disease,[10] which are associated with more rapid decline in lung function.[14] 
Interventions that aim to reduce the severity of exacerbations include prompting early 
recognition of symptoms and rapid use of antibiotics and/or corticosteroids either through 
seeking a primary care appointment or use of a self-treatment rescue medication pack.   
We evaluated telephone health coaching in people with mildly symptomatic COPD to explore 
the effectiveness of supporting self-management activities in this group of patients. We 
hypothesised that a nurse delivered telephone health coaching intervention to support self-
management, compared with usual primary care, would lead to improved COPD health 
related quality of life at 12 months follow-up and improve physical activity, smoking cessation 
and self-management behaviours, psychological health and self-efficacy. 
 
  
METHODS 
Design 
Patient self-management for COPD (PSM COPD) was a pragmatic multi-centre phase III 
randomised controlled trial (RCT) of a telephone health coaching intervention to support self-
management compared with usual care for people with COPD with mild dyspnoea. Details of 
the study protocol have been published elsewhere.[21] We followed the CONSORT 
guidelines for reporting RCTs of non-pharmacological treatments to report this study.[22] 
Following publication of the protocol in the ISRCTN clinical trial registry at the feasibility 
study phase, we changed the inclusion criterion for post-bronchodilator spirometry from 
below the lower limit of normal to forced expiratory volume in one second (FEV1)/forced vital 
capacity (FVC)<0.7, which is that recommended by the Global Initiative for Obstructive Lung 
Disease (GOLD).[6] We also included some additional subgroup analyses to those in the 
published protocol[21] (baseline FEV1 predicted [≥80/<80) and degree of limitation of 
activities in the St Georges Respiratory Questionnaire (SGRQ)). We embedded a sub-study 
that investigated participant recruitment materials. In this sub-study, general practices were 
randomised to send out either the standard participant information leaflet or a participant 
information leaflet which contained an additional web-address and QR (Quick Response) 
code to give access to web-based materials including podcasts about taking part in research 
in general and in the PSM-COPD trial in particular.[23] This did not alter any other trial 
processes.  
Participants  
Participants were recruited from 71 general practices within England located in Birmingham 
and West-Midlands South; Greater Manchester; North West Midlands and 
Oxfordshire/Gloucestershire. Patients aged 18 years or over were identified as eligible if they 
were (i) on the practice COPD register, thus had respiratory symptoms consistent with 
COPD; (ii) reported mild dyspnoea (MRC grades 1 (only breathless on strenuous exercise) 
  
or 2 (only get short of breath when hurrying on level ground or up a slight hill) on baseline 
assessment; (iii) had an FEV1/FVC<0.7 after post-bronchodilator spirometry (consistent with 
current UK guidance)[24] at the baseline assessment. If there was a contraindication or the 
person was unable or refused spirometry, a spirometry result reported from hospital within 
the last 18 months was used. General Practitioners (GPs) were asked to exclude patients 
who they considered to be inappropriate for the research team to invite to take part (e.g. 
terminal disease, severe psychiatric disorder). Potentially eligible patients were then sent a 
letter of invitation, information brochure and patient information leaflet from their GP, with a 
reply slip to the research team which included the MRC dyspnoea scale. If the MRC 
dyspnoea score was available on the COPD register, then only patients with recorded grade 
1 or 2 were invited, if this was not available, then all were invited.  
Baseline assessment 
Those who expressed an interest in the study were telephoned by a researcher and invited 
to a recruitment assessment at their practice, undertaken by a research nurse or trained 
researcher. Patients who attended baseline assessments were given the opportunity to 
discuss the study. Following informed consent, post-bronchodilator spirometry was 
undertaken, height and weight were measured and the patient was asked to complete a 
baseline questionnaire pack. This questionnaire pack included questions on patient 
demographics and the measures for the primary and secondary outcomes. A GENEactiv 
accelerometer was fitted on their non-dominant wrist, which they were asked to return by 
post in a pre-paid envelope after 7 days of continuous wear.  
Intervention and usual care  
This was a pragmatic trial with no constraints on GPs’ management of the participants in 
either group.  
  
The usual care group received a standard information leaflet about self-management of 
COPD.[25] The 13 page leaflet gave a definition of COPD, a detailed description of 
associated symptoms, how the illness can be managed with the use of inhalers, how to treat 
exacerbations, and details of other resources (e.g. British Lung Foundation, Smokefree-NHS 
Choices).   
The intervention consisted of nurse delivered telephone health coaching with supporting 
written documents, a pedometer and self-monitoring diary. This aimed to support self-
management in relation to smoking cessation; increase in physical activity; correct inhaler 
technique and medication adherence, and for those with recurrent exacerbations an 
increase in confidence in identifying an exacerbation early in order to commence rescue 
medication (antibiotics or steroids).   
The intervention was underpinned by Social Cognitive Theory,[26] and included education, 
monitoring and assessment of progress, and taught skills with the aim of increasing self-
efficacy.[27, 28] We incorporated best evidence for the promotion of physical activity 
(tailored, ongoing support, duration 6 months, use of pedometer).[29-32] The intervention, 
components are detailed in web appendix 1. The first telephone coaching session at one 
week post randomisation aimed to last 35-60 minutes (determined by the number of issues 
requiring discussion, such as current smoking), followed by three 15-20 minute telephone 
contacts at weeks three, seven and 11 with individually tailored written supportive materials 
following each telephone call (e.g. summary of goals agreed, physical activity diary, contact 
details for local services, information leaflet showing correct inhaler technique). This was 
followed by standard written prompts/information at 16 and 24 weeks.  
Nurses attended two days of training and practiced telephone coaching sessions with the 
research team. The telephone consultations were protocolised with the nurses following a 
proforma to guide the consultation. After each telephone call, the nurses briefly summarised 
the content of the call and any actions agreed; a sample of telephone consultations were 
  
recorded with the participants consent and reviewed by one researcher to explore 
compliance with the content of the intervention.  
Randomisation and masking 
Participants who had given informed consent and completed all the baseline measures were 
individually randomised in a 1:1 ratio to the intervention or usual care group stratified by 
centre. The allocation was made using a web-based programme hosted by the Primary Care 
Clinical Research and Trials Unit (PC-CRTU), University of Birmingham. Centre specific 
randomisation lists were produced by a statistician at the trials unit. The four recruitment 
centres were Birmingham and West-Midlands South; Greater Manchester; North West 
Midlands and Oxfordshire/Gloucestershire. Only the PC-CRTU had access to the allocation 
sequence. Participants were informed of their allocation at the end of the recruitment 
appointment; they were not masked to treatment allocation. Data were entered onto the 
study database by researchers at the University of Birmingham who were masked to 
treatment allocation.  
Outcome assessment   
We measured outcomes by postal questionnaire at six months to determine short–term 
change to the end of the intervention and at 12 months to determine whether any change 
was sustained. At 12 months, accelerometers were posted to participants with a follow-up 
telephone call to explain how to start the recording. They were asked to wear the 
accelerometers continuously for seven days and then to return them by post. Non-
responders were telephoned and given the option of completing the questionnaire over the 
telephone.   
Outcomes   
The primary outcome measure was health related quality of life at 12 months from 
randomisation measured using the St Georges Respiratory Questionnaire (SGRQ-C).[33] 
  
Scores range from 0 to 100, with higher scores indicating greater impairment of quality of 
life.   
Secondary outcomes were the SGRQ-C at 6 months, and the MRC dyspnoea scale,[34] 
self-reported physical activity (using the International Physical Activity Questionnaire 
(IPAQ)),[35] psychological morbidity (using the Hospital Anxiety and Depression Scale 
(HADS)),[36] self-efficacy for managing their COPD and undertaking physical activity (using 
the Stanford self-efficacy scale),[28] and health state utility using the EuroQoL 5 Dimensions 
5 Levels (EQ-5D-5L)[37] at 6 and 12 months post-randomisation. Smoking cessation rates 
and physical activity measured using GENEactiv accelerometers were assessed at 12 
months. Pre-specified exploratory outcomes were self-reported self-management activities 
(related to smoking cessation, medication adherence, care plans etc.) and health care 
utilisation at 6 and 12 months. An economic evaluation has also been undertaken, but will be 
reported elsewhere.  
Adverse events were reported by intervention participants during telephone calls and from 
the 6 and 12 month follow-up questionnaires; they were independently assessed by two 
independent clinicians. 
Statistical justification for sample size 
The sample size was determined to detect a significant difference in the SGRQ-C at one 
year. To have 80% power to detect a difference of 4 points (the minimal clinically significant 
difference)[38] from a baseline total score value of 39,[39] with a standard deviation (SD) of 
15 at the 5% level of significance requires 445 evaluable participants. Allowing for an attrition 
rate of 20% at 12 months, we needed 556 participants (278 per group).  
The power to detect differences in self-reported physical activity and in smoking cessation 
rates are detailed in the protocol paper.[21]  
Analysis  
  
All data were analysed by intention to treat. The main analyses compared primary and 
secondary outcome measures between treatment groups at 12 months post-randomisation 
to assess the long term effect of the self-management intervention. Data were also analysed 
at 6 months to assess the short term change.  
The primary outcome (SGRQ-C) and other continuous secondary outcome measures were 
analysed using a linear regression model. Ordered categorical secondary outcome 
measures (e.g. MRC dyspnoea scale) were analysed using an ordinal logistic regression 
model. All primary and secondary analyses were adjusted for baseline values and centre. 
Differences between treatment groups were summarised using suitable effect estimates 
(e.g. mean difference, odds ratio) with 95% confidence intervals (CI). A 5% statistical 
significance level was used. 
Exploratory outcome measures were not analysed using statistical modelling except for the 
count data. Binary/categorical outcome measures were analysed using Chi-squared or 
Fisher’s exact test and continuous measures were analysed using t-tests or a non-
parametric equivalent (e.g. Wilcoxon rank test). Measures of count were analysed using a 
Poisson regression model or negative binomial model as appropriate to obtain an incidence 
rate ratio (IRR). Models included an adjustment for baseline values and centre and an offset 
term for length of follow-up. 
A number of sensitivity analyses were performed for the SGRQ-C.  These included (i) a per-
protocol analysis which included only those participants who received all 4 telephone calls in 
the intervention group and excluded the one patient in the usual care group who received 
the intervention by mistake; (ii) an analysis to assess the effect of missing data, with patients 
with missing 12 month SGRQ-C scores being simulated by regression imputation using 
baseline data, with baseline score, age, gender, MRC score and treatment group used as 
predictors to impute missing scores. All participants were included in this analysis unless 
they had died by 12 months or both the baseline and 12 month SGRQ-C scores were 
  
missing; and (iii) an analysis which excluded participants where the 12 month SGRQ-C 
questionnaires were returned either early (>1 month prior to the assessment due date) or 
late (>65 days post the assessment due date). 
Subgroup analyses to explore the effects of the intervention in different patient subgroups 
were undertaken for the primary outcome (SGRQ-C total score only). The subgroups, pre-
specified in the statistical analysis plan included participant characteristics (age, gender, 
ethnicity, smoking status, baseline MRC dyspnoea score and number of co-morbidities), 
active engagers with the intervention (through increased physical activity, uptake of smoking 
cessation support or checking of inhaler technique), baseline level of physical activity (from 
both the IPAQ and the accelerometer data), baseline health related quality of life (SGRQ-C), 
baseline self-efficacy (Stanford) and baseline depression and anxiety (from HADS). Two 
post-hoc subgroup analyses were also undertaken for baseline FEV1 predicted (≥80/<80) 
and degree of limitation of activities in the SGRQ-C. A treatment group by subgroup 
interaction parameter was included in the linear regression model to assess whether there 
were any differences in the treatment effect across the different strata. Differences between 
treatment groups within subgroups were only examined if the interaction parameters were 
statistically significant (p<0.05).  
Details of the data available for the accelerometery analyses are provided in web appendix 
2.  
Patient involvement 
The study was supported by a COPD patient advisory group which provided input to a 
programme of research on COPD. The group met on a regular basis and one was a member 
of the trial management group for the duration of the study. The group commented on the 
initial design of the study, the burden of the trial assessment process, participant facing 
materials and on the content and material to support the intervention. Additionally, a lay 
  
representative was a member of the Trial Steering Group. At the end of the study the group 
commented on the findings and contributed to the dissemination plan.  
RESULTS 
We sent a screening questionnaire and invitation leaflet to 5279 people on the COPD 
registers of 71 general practices; 2066 responded with an interest in the study, but 920 were 
excluded as they had an MRC dyspnoea scale of 3 or more. We screened 728 people at 
their GP surgery between 18th March 2014 and 5th February 2015; 577 were eligible and 
randomised to telephone health coaching (n=289) or usual care (n=288) (figure 1). In total, 
531 (92%) of participants provided data at 6 months and 516 (89%) at 12 months follow-up. 
There was imbalance in the follow-up rates between the intervention (82.7%; 37 
withdrawals) and usual care (96.2%; 7 withdrawals) groups at 12 months, largely due to 
participants who wished to withdraw from the intervention also withdrawing from further 
follow-up. Of the 37 participants who withdrew from the intervention group, 4 withdrew 
before receiving any intervention and 16 withdrew during the intervention; 8 cited illness and 
10 cited intervention-related factors ranging from it being too demanding to insufficiently so. 
Seventeen participants withdrew after the 6 months follow-up. Participants who withdrew 
from the study did not differ in characteristics to the full sample. 
The characteristics of the participants are shown in Table 1. Participants were predominantly 
white; 63% were male; mean age 70.4 years; 23% were current smokers and only 19% were 
in paid employment. Participants had mild disease: mean FEV1 was 71.6% predicted, 193 
(33%) were GOLD stage 1 and 309 (54%) GOLD stage 2; 165 (28.6%) reported MRC level I 
dyspnoea and 270 (47%) reported medication for an exacerbation in the previous 12 
months. The mean SGRQ-C total score was 28.7. The study groups were generally well 
balanced in terms of participant characteristics, although there was a higher proportion of 
current smokers in the intervention group. The usual care group reported a higher level of 
self-reported moderate and vigorous activity, but this was not reflected in the accelerometry 
data at baseline. The accelerometry data for all participants showed that participants did a 
  
median of 31 minutes of moderate or vigorous activity in bouts of at least 10 minutes daily 
[IQR 0, 160]. Participants who did not provide data at 12 months were more likely to be in 
GOLD stage 3, to be smokers, had lower levels of self-reported physical activity and to live 
alone than responders.  
Table 1: Baseline characteristics of participants 
 Telephone PSM 
(N=289) 
Usual Care 
(N=288) 
Mean (SD) age in years 70.7 (8.8) 70.2 (7.8) 
Age ≥65 years 221 (76%) 231 (80%) 
Male 183 (63%) 183 (64%) 
White ethnic group 283 (98%) 284 (99%) 
Median [IQR] Age Completed Full Time Education1 15 [15-16] 15 [15-16] 
Highest Level of Qualification   
 No Formal Education 128 (44%) 135 (47%) 
 GCSE, CSE, O Level Equivalent 58 (20%) 63 (22%) 
 A-Level/AS Level or Equivalent 27 (9%) 24 (8%) 
 Degree Level or Higher 35 (12%) 41 (14%) 
 Other 40 (14%) 23 (8%) 
 Missing 1 (<1%) 2 (1%) 
Lives Alone 83 (29%) 69 (24%) 
Employment Status2   
 Paid Work 58 (20%) 53 (18%) 
 Unemployed/Looking for Work 3 (1%) 5 (2%) 
 Retired from Paid Work 216 (75%) 214 (74%) 
 Looking After Family/Home 8 (3%) 9 (3%) 
 Unable to Work Due to Health Problems 8 (3%) 7 (2%) 
 Other 5 (2%) 9 (3%) 
Clinical characteristics   
Current smoker 75 (26%) 55 (19%) 
Mean (SD) BMI (kg/m²) 27.1 (4.4) 27.4 (4.9) 
MRC Dyspnoea Scale   
 Level 1 89 (31%) 76 (26%) 
 Level 2 200 (69%) 212 (74%) 
Mean (SD) FEV1 Predicted (%) 71.2 (18.9) 72.1 (18.7) 
FEV1 Predicted (%)   
 <30 1 (<1%) 2 (1%) 
 30-49 39 (13%) 33 (11%) 
 50-79 160 (55%) 149 (52%) 
 ≥80 89 (31%) 104 (36%) 
Co-Morbidities   
  
 Telephone PSM 
(N=289) 
Usual Care 
(N=288) 
 Cancer 34 (12%) 37 (13%) 
 Diabetes 32 (11%) 36 (13%) 
 High Blood Pressure 135 (47%) 123 (43%) 
 Coronary Heart Disease 34 (12%) 44 (15%) 
 Heart Failure 15 (5%) 10 (3%) 
 Stroke/Mini-Stroke 16 (6%) 25 (9%) 
 Asthma 98 (34%) 100 (35%) 
 Tuberculosis 6 (2%) 10 (3%) 
 Osteoarthritis 46 (16%) 56 (19%) 
 Rheumatoid Arthritis 22 (8%) 25 (9%) 
 Osteoporosis 13 (5%) 20 (7%) 
 Depression 44 (15%) 57 (20%) 
 Other Condition 37 (13%) 52 (18%) 
Medication taken regularly for lung problems   
 Beta-2 Agonist 201 (70%) 197 (68%) 
 Inhaled Steroid 27 (9%) 39 (14%) 
 Atrovent/Spiriva 109 (38%) 117 (41%) 
 Seretide 88 (30%) 92 (32%) 
 Symbicort 33 (11%) 21 (7%) 
 Uniphylline/Aminophylline Tablets 7 (2%) 6 (2%) 
 Steroid Tablets 5 (2%) 9 (3%) 
Antibiotic and/or Steroid Course in past 12 Months 135 (47%) 135 (47%) 
Health related quality of life   
 Mean (SD) SGRQ-C Total Score 27.8 (14.6) 29.5 (14.5)  
 Mean (SD) SGRQ-C Symptoms Score 48.5 (21.7) 47.9 (20.7) 
 Mean (SD) SGRQ-C Activity Score 36.3 (21.0) 38.7 (21.3) 
 Mean (SD) SGRQ-C Impact Score 15.4 (13.4) 17.6 (13.9) 
 Mean (SD) EQ-5D-5L 0.90 (0.13) 0.89 (0.13) 
Anxiety and Depression using HADS   
 Mean (SD) anxiety subscale score 3.8 (3.4) 4.3 (3.8) 
 Mean (SD) depression subscale score 2.9 (2.6) 3.1 (2.8) 
Physical activity   
 Mean (SD) minutes of MVPA/week by 
 accelerometry 
372.1 (305.1) 379.1 (282.9) 
 Mean (SD) moderate MET minutes/week using
 IPAQ 766.4 (1253.9) 941.5 (1437.6) 
 Mean (SD) vigorous MET minutes /week using
 IPAQ 
809.4 (1771.5) 910.2 (1997.4) 
Self-Efficacy   
Mean (SD) Stanford Self Efficacy Score 8.3 (1.6) 8.0 (1.7) 
1 One Subject in the Telephone PSM Group Never Went to School. 
2 Not mutually exclusive, participants could tick all that applied. 
 
  
 
Intervention delivery  
The dose and coverage of intervention delivery was high: 86.4% (999/1156) of the 
scheduled calls were delivered and 218 (75.4%) of participants received all four calls. The 
average duration of calls was 39.2 minutes (SD 10.7) for the first call, then 23.8 (SD 9.2), 
21.4 (SD 8.6) and 20.6 minutes (SD 8.7) for the second, third and final calls respectively. 
Nurses briefly noted content and duration of each telephone coaching session. Most calls 
were delivered by the same nurse, although sometimes this was not possible due to illness 
or leave. Smoking was discussed in a third of sessions, physical activity in over 99%, inhaler 
technique in 90% and action planning in 88% of all calls. SMART goals were set in 57% of 
calls for physical activity, in 11% for smoking cessation and in 9% for inhaler technique to be 
checked. 
Primary outcome 
At 12 months, there was no significant difference in the total SGRQ-C score (mean 
difference -1.3, 95% confidence interval -3.6 to 0.9; p=0.2), although the direction favoured 
the intervention group. The mean difference in the SGRQ-C activity score was of borderline 
significance favouring the intervention group (-3.2, 95% confidence interval -6.3 to 0.0; 
p=0.05). There was no significant difference between groups for the SGRQ-C symptoms or 
impact scores (table 2).  
  
Table 2: Comparison of primary and secondary outcomes  
 
 Baseline 6 months 12 months 
 
 
 Telephone 
PSM 
mean (sd) 
Usual Care 
mean (sd) 
Telephone 
PSM 
mean (sd) 
Usual Care 
mean (sd) 
Mean 
difference 
(95% CI) 
p- 
value 
Telephone 
PSM 
 
mean (sd) 
Usual Care 
mean (sd) 
Mean 
difference 
(95% CI) 
p- 
value 
Health related Quality of Life         
 SGRQ-C total1 
 
N=277 
27.8 (14.6) 
N=272 
29.5 (14.5) 
N=222 
28.6 (17.1) 
N=237 
30.5 (16.7) 
-0.3 
(-2.3 to 1.7) 
0.8 N=217 
27.9 (15.7) 
N=256 
30.9 (17.0) 
-1.3 
(-3.6 to 0.9) 
0.2 
 SGRQ-C symptom1 
 
N=284 
48.5 (21.7) 
N=279 
47.9 (20.7) 
N=241 
49.5 (22.6) 
N=266 
49.2 (21.4) 
-0.04  
(-2.9 to 2.8) 1.0 
N=230 
49.3 (21.4) 
N=273 
50.1 (22.6) 
-1.9  
(-4.9 to 1.1) 0.2 
 SGRQ-C activity1 
 
N=281 
36.3 (21.0) 
N=279 
38.7 (21.3) 
N=229 
36.0 (22.7) 
N=252 
37.9 (23.9) 
0.4  
(-2.3 to 3.2) 0.8 
N=224 
33.7 (21.1) 
N=260 
39.2 (24.4) 
-3.2  
(-6.3 to 0.0) 0.05 
 SGRQ-C impact1 
 
N=286 
15.4 (13.4) 
N=280 
17.6 (13.9) 
N=233 
16.9 (16.3) 
N=255 
19.0 (15.5) 
-0.7  
(-2.8 to 1.4) 0.5 
N=225 
16.5 (15.2) 
N=261 
19.3 (15.6) 
-1.1  
(-3.3 to 1.1) 0.3 
 EQ-5D-5L2 
 
N=285 
0.90 (0.13) 
N=280 
0.89 (0.13) 
N=244 
0.88 (0.16) 
N=272 
0.87 (0.14) 
0.01  
(-0.01 to 
0.03) 
0.3 
N=235 
0.87 (0.14) 
N=270 
0.86 (0.17) 
0.01  
(-0.01 to 
0.03) 
0.4 
Anxiety and Depression         
 HADS anxiety 
 subscale 
 score1 
N=286 
3.8 (3.4) 
N=285 
4.3 (3.8) 
N=243 
3.8 (3.8) 
N=279 
4.5 (4.0) 
-0.3  
(-0.8 to 0.2) 0.2 
N=227 
4.0 (3.8) 
N=267 
4.7 (4.0) 
-0.06  
(-0.6 to 0.4) 0.8 
 HADS 
depression 
 subscale 
score1 
N=287 
2.9 (2.6) 
N=285 
3.1 (2.8) 
N=244 
3.1 (3.0) 
N=279 
3.5 (3.1) 
-0.2  
(-0.6 to 0.1) 0.2 
N=228 
3.3 (3.3) 
N=270 
3.8 (3.4) 
-0.1  
(-0.6 to 0.4) 0.6 
Self-Efficacy         
 Stanford Self 
 Efficacy 
 Score2 
N=287 
8.3 (1.6) 
N=284 
8.0 (1.7) 
N=247 
8.1 (1.7) 
N=275 
7.8 (1.8) 
0.2 (-0.07 to 
0.4) 0.2 
N=228 
8.1 (1.6) 
N=272 
7.7 (1.8) 
0.1  
(-0.1 to 0.4) 0.3 
Physical Activity (accelerometry)         
  MVPA 
minutes/week2 
N=263 
372.1 
(305.1) 
N=259 
379.1 
(282.9) 
- - - - N=179 
346.5 
(276.6) 
N=232 
315.5 
(256.1) 
11.8  
(-21.1 to 
44.8) 
0.5 
  
Physical Activity (IPAQ)         
  Total MET 
 minutes/week
2 
N=230 
3242.2 
(3284.2) 
N=236 
3265.8 
(3480.6) 
N=202 
3786.0 
(3685.7) 
N=237 
2920.6 
(3195.0) 
924.7 
(318.3 to 
1531.1) 
0.003 N=191 
3214.3 
(3578.4) 
N=223 
2738.1 
(3249.9) 
410.0 
(-235.7 to 
1055.7) 
 
0.2 
 Walking MET 
 minutes/week
2 
N=249 
1496.0 
(1324.6) 
N=253 
1371.0 
(1249.0) 
N=216 
1728.8 
(1390.6) 
N=248 
1404.2 
(1244.0) 
283.4 
(55.2 to 
511.6) 
0.02 
N=200 
1588.5 
(1386.7) 
N=234 
1362.7 
(1318.2) 
161.5 
(-86.2 to 
409.3) 
 
0.2 
 Moderate 
MET 
 minutes/week
2  
N=267 
766.4 
(1253.9) 
N=265 
941.5 
(1437.6) 
N=236 
950.8 
(1399.7)  
N=268 
732.9 
(1208.2)  
233.9 
(10.6 to 
457.1) 
0.04 
N=218 
765.9 
(1256.4)  
N=261 
628.6 
(1164.8)  
130.1 
(-83.9 to 
344.0) 
0.2 
  Vigorous MET 
minutes 
 /week2  
N=271 
809.4 
(1771.5) 
N=282 
910.2 
(1997.4) 
N=229 
1050.5 
(2212.7)  
N=270 
728.7 
(1656.6)  
335.8 
(23.2 to 
648.4) 
0.04 
N=218 
864.4 
(1994.3)  
N=264 
705.3 
(1674.0)  
160.1 
(-141.1 to 
461.3) 
0.3 
     Odds Ratio  
(95% CI)3 
p- 
value 
  Odds Ratio 
(95% CI)3 
p- 
value 
MRC Dyspnoea Scale   0.8 
(0.6 to 1.2) 
0.4   1.1 
(0.7, 1.5) 
0.8 
 Level 1 89 (31%) 76 (26%) 77 (32%) 84 (32%)   69 (31%) 74 (28%)   
 Level 2 200 (69%) 212 (74%) 137 (58%) 158 (60%)   137 (61%) 163 (61%)   
  Level 3 - - 14 (6%) 18 (7%)   16 (7%) 27 (10%)   
  Level 4 - - 8 (3%) 5 (2%)   4 (2%) 5 (2%)   
  Level 5 - - 1 (<1%) 0 (-)   0 (-) 0 (-)   
Smoking cessation         
     Quit Smoking† 75 (26%) 55 (19%) 14 (22%) 9 (18%) - 0.6 7 (13%) 13 (25%) - 0.1 
  
Data are presented as mean (SD) or n (%) as appropriate. 
  † Baseline data is reported as current smokers at baseline. Only patients who reported they were current smokers at baseline were included in the analyses 
on quitting smoking at 6 and 12 months. 
1Telephone PSM compared to usual care (negative values favour Telephone PSM). 
2Telephone PSM compared to usual care (positive values favour Telephone PSM). 
3Telephone PSM compared to usual care (Odds Ratio >1 favours Telephone PSM). 
  
Secondary outcomes 
At six months, there were no significant differences in the SGRQ-C total and sub-scores 
(table 2). At six and 12 months, there were also no differences in the EQ-5D-5L, HADS, 
Stanford self-efficacy scale or level of breathlessness (MRC) (table 2). At six months, total 
self-reported physical activity, walking, moderate and vigorous intensity activity were all 
significantly higher in the intervention arm (table 2). Whilst differences still favoured the 
intervention arm at 12 months, they did not remain statistically significant. There was no 
difference in moderate or vigorous activity measured using accelerometry at 12 months. 
There was also no difference in smoking cessation rates at 6 and 12 months (table 2). 
Health care utilisation 
At six months, intervention participants reported significantly lower GP and pharmacist 
consultations, but higher all-cause emergency department visits. There were no differences 
at 12 months (table 3). At six and 12 months, 106 (43%) and 89 (37%) of the intervention 
group respectively had been prescribed at least one course of antibiotics compared to 105 
(37%) and 96 (35%) of the usual care group. 
  
Table 3: Health care utilisation 
 Baseline 6 months Incidence Rate 
Ratio¹ 
(95% CI) 
p-
value² 
12 months Incidence Rate 
Ratio¹ 
(95% CI) 
p-
value² 
 Telephone 
PSM  
Usual Care 
 
Telephone 
PSM 
Usual Care 
 
  Telephone PSM 
Usual Care 
 
  
Hospital Admissions           
 All Cause 
N=277 
0.11 (0.4) 
N=281 
0.12 (0.4) 
N=248 
0.07 (0.3) 
N=283 
0.08 (0.3) 
0.86 (0.45 to 
1.62) 0.6 
N=239 
0.06 (0.3) 
N=277 
0.06 (0.3) 
0.90* (0.39 to 
2.09) 0.8 
 Respiratory N=281 0.02 (0.2) 
N=283 
0.02 (0.1) 
N=248 
0.02 (0.1) 
N=283 
0.03 (0.2) 
0.55* (0.15 to 
2.07) 0.4 
N=239 
0.01 (0.1) 
N=277 
0.01 (0.1) 
0.56* (0.08 to 
4.11) 0.6 
Emergency department           
 All Cause N=286 0.22 (0.5) 
N=280 
0.23 (0.6) 
N=248 
0.33 (1.8) 
N=283 
0.16 (0.5) 
1.87* (1.06 to 
3.27) 0.03 
N=238 
0.26 (0.8) 
N=276 
0.23 (0.7) 
1.06* (0.62 to 
1.83) 0.8 
 Respiratory N=286 0.04 (0.2) 
N=282 
0.02 (0.1) 
N=248 
0.04 (0.2) 
N=283 
0.03 (0.2) 
1.48* (0.50 to 
4.43) 0.5 
N=239 
0.04 (0.2) 
N=277 
0.01 (0.1) 
2.85* (0.67 to 
12.20) 0.2 
Primary care consultations           
 GP -all Cause N=288 1.18 (1.7) 
N=285 
1.23 (1.5) 
N=243 
1.41 (1.5) 
N=282 
1.76 (2.2) 
0.80* (0.66 to 
0.96) 0.02 
N=236 
1.45 (1.8) 
N=272 
1.67 (1.8) 
0.85* (0.70 to 
1.03) 0.1 
Practice Nurse -all Cause N=288 0.60 (1.8) 
N=285 
0.65 (1.4) 
N=243 
0.71 (1.5) 
N=282 
0.72 (1.4) 
0.98* (0.73 to 
1.31) 0.9 
N=234 
0.56 (1.0) 
N=272 
0.67 (1.0) 
0.81* (0.62 to 
1.07) 0.1 
Pharmacist -all Cause N=288 0.10 (0.9) 
N=285 
0.13 (0.6) 
N=243 
0.05 (0.4) 
N=282 
0.17 (0.8) 
0.27* (0.10 to 
0.75) 0.01 
N=233 
0.10 (0.6) 
N=268 
0.11 (0.5) 
0.75* (0.29 to 
1.91) 0.5 
 Respiratory N=186 0.63 (0.9) 
N=190 
0.84 (1.1) 
N=164 
0.90 (1.1) 
N=197 
0.96 (1.3) 
0.99* (0.72 to 
1.35) 0.9 
N=132 
0.77 (1.0) 
N=167 
0.83 (1.2) 
0.84* (0.60 to 
1.19) 0.3 
Data are presented as mean (SD). 
¹ Telephone PSM compared to Usual Care (Incidence Rate Ratio <1 favours Telephone PSM).   
² Statistical Significance determined from a chi-squared test. 
*Estimate from a negative binomial model rather than a Poisson regression model 
  
Activities targeted by the telephone health coaching intervention 
Physical activity and smoking cessation rates have been described above. There was no 
difference between the groups in smoking quit attempts in the previous 6 months or 
attendance at smoking cessation services at either follow-up point. At six months, 
participants in the intervention group reported improved medication adherence, with 
significantly higher proportions having an inhaler check in the past six months (68% vs. 
55%), an agreed care plan with a health care provider (44% vs. 30%), written advice about 
what to do if symptoms worsened (23% vs. 17%) and having an antibiotic rescue pack (37% 
vs. 29%). However, they did not report improved confidence in the use of rescue packs. At 
12 months, many of these improvements were sustained (table 4). 
  
Table 4: Self-reported self-management behaviours  
   6 months p-value 12-months p-value 
 Telephone 
PSM 
Usual care Telephone 
PSM 
Usual care  Telephone 
PSM 
Usual care  
Smoking quit attempt in past 6 
months 
 
- 
 
- 
29 (54%) 21 (49%) 0.7 30 (58%) 21 (53%) 0.5 
Attendance at smoking 
cessation service1 
- - 3 (10%) 1 (5%) 0.6 3 (10%) 4 (19%) 0.4 
Median medication adherence 
score2 (0-24) (IQR, n) 1 (0-2, 273) 1 (0-2, 265) 1 (0-2, 219) 1 (0-2, 255) 0.01 1 (0-1, 218) 1 (0-2, 255) 0.1 
Inhaler check in past 6 months - - 168 (68%) 157 (55%) 0.01 156 (65%) 153 (55%) 0.02 
Agreed a care plan with health 
care provider3 
        
 in past 6 months 80 (28%) 82 (29%) 108 (44%) 85 (30%) 0.002 79 (33%) 75 (27%) 0.02 
 >6 months ago 25 (9%) 26 (9%) 53 (21%) 70 (25%)  72 (30%) 70 (25%)  
 never 165 (57%) 156 (54%) 63 (25%) 104 (37%)  68 (28%) 111 (40%)  
Written advice on what to do if 
symptoms get worse 49 (17%) 49 (17%) 57 (23%) 47 (17%) 
0.05 54 (23%) 52 (19%) 0.1 
Has antibiotic rescue pack 77 (27%) 75 (26%) 93 (37%) 81 (29%) 0.02 97 (40%) 83 (30%) 0.02 
 confident in its use 71 (92%) 68 (91%) 85 (91%) 76 (94%) 0.5 95 (98%) 76 (92%) 0.1 
Has steroid rescue pack 56 (19%) 51 (18%) 63 (25%) 60 (21%) 0.2 70 (29%) 58 (21%) 0.03 
 confident in its use 52 (93%) 47 (92%) 53 (84%) 55 (92%) 0.4 65 (93%) 54 (93%) 1.0 
1Denominator is participants who made a quit attempt in previous 6 months 
2Medical Adherence Score: Ranges from 0-24, where low scores are good and high scores are bad. 
3Baseline Assessment Only: (Yes < 12 months, Yes ≥12 months, No). 
Percentages do not add up to 100% due to missing data  
 
  
Sensitivity and subgroup analyses 
There were no differences in the findings for (i) the per-protocol analysis (ii) when regression 
imputation was used to impute missing data; or (iii) when the analysis excluded 
questionnaires returned either early or late (see web appendix 3). Subgroup analyses also 
found no evidence that the effect size differed by age, gender, ethnicity, comorbidities, 
baseline MRC level, smoking status, HADS, physical activity, FEV1 predicted (≥80/<80), 
degree of limitation of activities in the SGRQ-C, active engagers, or self-efficacy. There was 
some evidence of an interaction with baseline SGRQ-C (p=0.04); with a greater benefit for 
intervention in participants with a baseline score of ≥25 (i.e. those with poorer quality of life) 
(mean difference -3.0, 95% CI -6.4 to 0.3) compared to those with a baseline score <25 (2.3, 
95% CI -1.6 to 6.2).   
Adverse events 
There were 44 serious adverse events reported by participants; 24 in the intervention and 20 
in the usual care arm. No serious and related events occurred. The five deaths were all in 
the intervention group and were due to cor pulmonale, stroke, ruptured aortic aneurysm, and 
malignancy (2), none were considered to be related to the intervention.   
  
  
DISCUSSION  
Principal findings 
This trial is the first to evaluate the effectiveness of a nurse-led telephone health coaching 
intervention to support self-management for patients living with mild symptoms of COPD. 
Whilst we showed an improvement in self-reported self-management activities in the 
telephone coaching group compared to usual care, we did not observe a significant 
difference in our primary outcome of health related quality of life measured by the SGRQ-C, 
nor in the impact, symptom or activity domains, although the confidence intervals did include 
the minimal clinically important difference of 4 points for the activity and symptom domains. 
Self-reported physical activity was higher at 6 months in the intervention group, but this was 
not sustained at 12 months. In addition, activities targeted by the intervention, including 
patients asking a health care professional to check their inhaler technique, asking their 
general practitioner to agree a care plan and having a rescue pack were significantly higher 
in the intervention group at 6 and 12 months follow-up, compared to usual care, suggesting 
that a proportion of intervention participants adopted active self-management.  
Comparison with other studies 
Our approach was novel in comparison to other trials of self-management and telephone 
coaching interventions by targeting people with mildly symptomatic disease. Most previous 
trials of COPD self-management have excluded participants with GOLD stage I (mild airflow 
obstruction),[9, 40] whereas a third of our participants, were in this category, as we 
particularly wanted to evaluate an intervention for more mildly affected patients, who are a 
clinically important, but largely neglected group despite having a reduced health related 
quality of life.[41]  
Systematic reviews of self-management interventions have reported significant 
improvements in COPD related quality of life, measured by the SGRQ[9, 40, 42] with a mean 
  
difference of -2.40 at 12 months follow-up.[42] All reviews reported effects larger than the -
1.3 points difference at 12 months found in our trial. Health related quality of life has been 
favoured as the main outcome for trials of COPD self-management as functional status is 
important to patients and is sensitive to change, whilst lung function has a natural variation 
making it difficult to interpret change over short follow-up periods. Compared to other studies 
of self-management in COPD, even those in milder populations,[39] the SGRQ total score in 
our study was very low at baseline (representing a good HRQoL). This potentially led to a 
floor effect, where change may be unlikely to be achievable, or improvement may only be 
observed over a much longer time scale. However for the activity sub-score of the SGRQ, 
the mean difference at 12 months (-3.2) found in our trial compares well with those of the 
systematic reviews, which report statistically significant mean differences of -2.21[40] and -
2.75.[9] These findings are consistent with the significant differences found at six months (at 
the end of the PSM-COPD intervention) in self-reported physical activity (IPAQ). However, 
this result of reduced limitations to physical activities was not reflected in the self-reported 
quantity or intensity of physical activity (IPAQ) or our objective measures of physical activity 
where there were no differences between groups at 12 months.  
An Australian RCT of a 12 month intensive telephone health mentoring intervention for 
primary care patients with moderate to severe COPD also did not report a difference in the 
SGRQ at 12 months; but did achieve greater improvements in self-management capacity 
and in COPD knowledge than usual care.[43] Similar to our trial, a 12 week RCT of an 
intensive automated telecoaching programme reported significant improvements in physical 
activity and the functional domain of the Clinical COPD Questionnaire, but not health related 
quality of life (COPD Assessment Test) at the end of the 12 week intervention period.[44] 
Conversely, an RCT of telephone-mentoring for home-based walking demonstrated no 
benefit in exercise capacity in patients with COPD prior to commencing a pulmonary 
rehabilitation programme, and also had a high withdrawal rate.[45] In keeping with our 
findings, a rapid review of 30 RCTs of the effects of telephone health coaching to support 
  
self-management of long-term conditions reported improvements in health behaviours, but 
did not find conclusive evidence of improvements in quality of life.[5]  
Observed short-term improvements in self-reported physical activity may have required a 
longer duration of support or intermittent maintenance activities to sustain changes. Primary 
care consultations were also lower in the intervention group at 6 months, which again may 
reflect the increased telephone contact in this period. A consistent message of the 
intervention was for intervention participants to use their routine appointments with primary 
care for their inhaler technique to be checked or to discuss a care or action plan and it 
appears that participants heeded this message and did not book additional consultations for 
self-management advice or support.  
Strengths and limitations of this study 
There were many strengths of this study. Firstly, focusing on a mildly symptomatic patient 
group who are largely excluded from other trials provided novelty and potential for clinical 
benefit. We used a multi-centre study design incorporating a large sample of GP practices 
representative of the general UK population; a pragmatic design to accommodate a broad 
patient group with no selection by motivation to change health behaviours; spirometry was 
undertaken using trained staff and quality assured and we achieved a good follow-up rate. 
The intervention was underpinned by social cognitive theory and included techniques such 
as goal setting that have been shown to be effective in modifying behaviour[46] and was at 
an intensity that might potentially be delivered in a publically funded health service. We 
achieved good fidelity of delivery of the intervention, with 75% of intervention participants 
receiving all four calls and only 4 participants receiving none. There did not appear to be any 
contamination or change in behaviour in the usual care group with their self-reported self-
management behaviours remaining static throughout the trial. In keeping with the pragmatic 
nature of this intervention, we did not check whether those who checked inhaler technique 
  
had adequate training, but this is a core component of primary care management of 
COPD.[24] 
Our study has some limitations. The intervention was in a group of people with only mild 
symptoms of breathlessness, who may not have considered themselves ill, thus a high 
degree of motivation may have been needed to take part. Highly motivated patients would 
be more likely to self-manage their condition and change lifestyle behaviours. Our sample 
reported high levels of regular physical activity exceeding the lower recommended amount of 
moderate or vigorous activity per week at baseline; so, despite our efforts to recruit all 
eligible patients from primary care there is likely to have been self-selection of people to the 
study, which may have affected capacity to improve, which is a feature of most behaviour 
change trials.  The intervention did not meet the needs of some participants who withdrew 
from the intervention and in some cases also withdrew from the trial, resulting in an 
imbalance in follow-up rates between study arms. The participants who withdrew gave 
reasons including feeling that the intervention did not meet their needs as they were already 
physically active and some that were too unwell following an exacerbation. This may point to 
the need for more individual tailoring than actually occurred. In addition, delivery by 
telephone may give less opportunity for the building of rapport between the participant and 
nurse. Issues of rapport, acceptability and tailoring of the intervention will be addressed in 
more detail in a separate publication of the qualitative evaluation. We did not observe large 
differences in the characteristics of those who withdrew from the trial, nor any differences in 
the interpretation of the primary outcome with a sensitivity analysis to assess the impact of 
missing data. The power calculation was based on detecting a 4 point difference in the 
SGRQ-C at 1 year (mean score 39, SD 15).  Although participants in PSM-COPD had less 
severe disease at baseline (28.7) than expected, the SD was 14.5 meaning we still have 
80% power to detect the 4 point difference.  However, due to the lower SGRQ score at 
baseline, this 4 point difference now corresponds to a 14% proportional reduction compared 
to the 10% proportional reduction in the original sample size.  
  
We trained our nurses for two days with further role plays and group calls to discuss 
challenges once the intervention had started. Our evaluation of the logs of their telephone 
calls and audio-recorded calls identifies a variation in communication style from patient 
centred to a more directive approach. Further, due to the nature of recruitment across 
different sites, the distribution of calls completed by nurses was uneven. It was apparent that 
some participants were reluctant to set physical activity goals. It is possible that longer nurse 
training would have led to greater communication skills and more behavioural change, but 
this was a pragmatic study that aimed to evaluate an intervention that could be rolled out in 
practice. It is possible that a longer intervention duration, with calls beyond three months, 
would have led to greater effects and that in our group with predominantly mild disease, 
follow-up beyond 12 months might be needed to detect changes.  
Implications for clinicians and policy 
Adding telephone health coaching to support self-management did not improve health 
related quality of life in our patient population with only mildly symptomatic disease and who 
were already quite physically active at baseline. It did, however, lead to an increase in self-
reported physical activity at 6 months, which is likely to result in health benefits,[15, 16] and 
self-management activities which are likely to reduce the frequency and severity of 
exacerbations. Whilst there is still uncertainty about best practice for managing people with 
mildly symptomatic disease, inhaled therapies are widely used in this group and improved 
engagement with education about correct delivery technique will help to realise improved 
outcomes for these patients.[18, 19]  Currently, whilst self-management support is 
recommended, it is not likely to be well implemented.[47] Much evidence for COPD self-
management support comes from patients recruited from secondary care and there needs to 
be a synthesis of the findings of support for self-management in patients recruited from a 
primary care setting. It may be that among people with mildly symptomatic disease, self-
management support should be provided for those with poorest health related quality of life, 
which is the greatest predictor of future quality of life,[48] or in those with the most frequent 
  
exacerbations.[14] It may also be that a different health related quality of life outcome 
measure is needed for people with mild/early COPD that addresses limitations specific to the 
stage of their disease.   
There is a lack of evidence of effective interventions for patients with mild COPD and this 
trial, while improving some self-management behaviours, did not show evidence of clinical 
benefit. There remains a need to identify successful interventions for COPD patients with 
milder symptoms and this also has clear implications for screening or case-finding activities, 
which would identify patients with mild disease, and cannot be recommended whilst there is 
a lack of effective treatment options for this patient group. There are wider implications in the 
use of telephone health coaching; a rapid review reported that it appears to be most effective 
in vulnerable populations, who have difficulty accessing health services,[4] which is not 
reflective of our study population. Supporting self-management in people with early disease, 
or risk factors, remains a challenge. Apart from diabetes prevention programmes, health 
services generally focus self-management support and rehabilitation services on people with 
more advanced disease, but there is the potential for considerable health and health service 
gains if we could facilitate self-management in people with early disease and slow their 
decline. Establishing whether this is possible will require long-term follow-up studies.  
Conclusions and policy implications 
A novel telephone health coaching intervention to promote behaviour change in patients with 
mild symptoms of dyspnoea in primary care led to changes in self-management activities, 
but did not significantly improve health related quality of life. There remains a clear need to 
identify risk mitigating interventions that can effectively prevent or delay disease progression 
in this patient group.    
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Figure Legend 
Figure 1: PSM COPD Consolidated Standards of Reporting Trials (CONSORT) trial 
profile 
  
Summary box 
WHAT IS ALREADY KNOWN ON THIS TOPIC 
Recent policy for the prevention and management of long term conditions focusses on 
efforts to prevent onset or slow progression of disease early in the disease trajectory. This 
prevention paradigm has only recently been adopted in COPD.  
Systematic reviews have shown that self-management support for people with COPD is 
effective in improving health related quality of life and in reducing hospital admissions, but 
the evidence comes largely from people with moderate or severe disease and predominantly 
recruited from secondary care.  
 
WHAT THIS STUDY ADDS 
Our study, in people with mildly symptomatic COPD recruited from primary care, showed 
that telephone health coaching comprising components that were theoretically associated 
with slowing decline of lung function, did improve self-management activities that were 
targeted by the intervention, but did not improve health related quality of life over the 12 
month follow-up period. 
  
Web appendix 1: Outline of the intervention components 
Week 1 
Telephone: 
Medication management: Inhaler technique: timing of last check, set goal to get technique checked. 
Medication adherence (if relevant) –memory prompts, restructuring environment, support from 
partner. 
Smoking: Discussion of smoking behaviours, quit attempts and barriers to quit. Encouragement to set 
goal to contact smoking cessation service and to seek social support to support a quit attempt. 
Physical activity: current levels and breathlessness, goal to increase activity (duration and or intensity) 
and record in diary. 
Action planning: discussion of management of exacerbations, did they have written action plan, 
confidence with use of rescue pack. Prompt to discuss at routine appointment with GP if lacking 
understanding or confidence. 
Postal:  
Physical activity booklet including information on benefits for COPD and overcoming barriers 
Physical activity diary 
Pedometer with instructions 
Smoking information booklet (smokers only) with contact details of smoking cessation service 
Inhaler technique instruction leaflet 
 
Week 3 
Telephone: 
Discussion of progress with goals set in previous session and any barriers to achieving goals. 
Review of physical activity levels and setting of new goals. 
Discussion of smoking, medication management and action planning as required. 
Postal: 
Information on opportunities for physical activity in the locality 
Information leaflet: What are SMART goals? 
SMART goals sheet 
 
Week 7 
Telephone: 
Discussion of progress with goals set in previous session and any barriers to achieving goals. 
Review of physical activity levels and setting of new goals. 
Discussion of smoking, medication management and action planning as required. 
Postal: 
SMART goals sheet 
 
Week 11 
Telephone: 
Discussion of progress with goals set in previous session and any barriers to achieving goals. 
Review of physical activity levels and setting of new goals. 
Discussion of smoking, medication management and action planning as required. 
Postal: 
SMART goals sheet 
 
Week 16 
Postal SMART goals sheet 
 
Week 24 
Postal: 
Information on opportunities for physical activity in the locality 
Leaflet on tips for sustaining physical activity 
  
 
Web appendix 2: Accelerometry methods and adherence 
At the baseline assessment a GENEactiv accelerometer was fitted on the participant’s non-
dominant wrist, which they were asked to return by post in a pre-paid envelope after 7 days 
of continuous wear. At 12 month follow-up accelerometers were posted to participants with a 
follow-up telephone call to explain how to start the recording. They were asked to wear them 
continuously for 7 days and return them by post. Non-responders were telephoned and 
given the option of completing the questionnaire over the telephone.   
Analysis 
Data were collected in 60 second epochs. In order to be considered a valid day, participants 
needed to wear the accelerometer for at least 10 waking hours. A minimum of 5 days of valid 
data was necessary for inclusion in the final analysis. The criterion for non-wear was 120 
minutes of zero counts. The default cut-points for adult physical activity were used to 
determine the amount of time spent in moderate to vigorous physical activity. These cut-
points in g.min were 483 for the threshold from sedentary to light activity, 678 for moderately 
intense activity and 2264 for vigorous activity.  
Adherence 
At baseline 535 participants returned an accelerometer with data on, of which 522 (90.5%) 
had valid data for inclusion in the analyses. At 12 months follow-up, 416 accelerometers 
were returned with data, of which 411 had valid data for analysis; this was 71.2% of the 
initial sample.  
  
Web appendix 3: Results of sensitivity analyses for the PSM-COPD study 
 
 Baseline 12 months 
 Telephone 
PSM 
mean (sd) 
Usual Care 
 
mean (sd) 
Telephone 
PSM 
mean (sd) 
Usual Care 
 
mean (sd) 
Mean 
difference¹ 
(95% CI) 
p-
value 
Per-protocol analysis 
 SGRQ-C total 26.5 (13.5) 29.5 (14.5) 27.6 (14.6) 30.8 (17.0) -1.4 (-3.6, 0.8) 0.2 
 SGRQ-C symptom 48.1 (21.1) 47.8 (20.7) 49.2 (21.2) 50.0 (22.7) -1.9 (-4.9, 1.2) 0.2 
 SGRQ-C activity 34.1 (19.8) 38.7 (21.3) 33.9 (20.1) 39.3 (24.4) -2.4 (-5.6, 0.8) 0.1 
 SGRQ-C impact 14.4 (12.3) 17.5 (13.9) 15.8 (13.8) 19.3 (15.6) -1.6 (-3.8, 0.5) 0.1 
Analysis to assess impact of assessment window 
 SGRQ-C total 27.1 (13.9) 29.1 (14.2) 28.1 (15.5) 30.7 (16.8) -1.1 (-3.3, 1.1) 0.3 
 SGRQ-C symptom 48.6 (21.2) 47.7 (20.7) 49.3 (21.4) 50.0 (22.6) -1.6 (-4.7, 1.4) 0.3 
 SGRQ-C activity 35.0 (19.9) 38.5 (21.1) 34.4 (20.7) 39.1 (24.2) -2.5 (-5.6, 0.7) 0.1 
 SGRQ-C impact 14.8 (12.8) 17.0 (13.4) 16.4 (14.8) 19.2 (15.3) -1.1 (-3.3, 1.0) 0.3 
Imputation to assess impact of missing data 
 SGRQ-C total 27.9 (14.5) 29.5 (14.5) 28.5 (15.9) 31.1 (17.3) -1.4 (-3.4, 0.6) 0.2 
 SGRQ-C symptom 48.3 (21.8) 47.7 (20.5) 48.6 (21.1) 50.2 (22.4) -2.0 (-4.7, 0.7) 0.1 
 SGRQ-C activity 36.3 (21.0) 38.5 (21.2) 34.7 (21.4) 39.2 (23.8) -3.0 (-5.9, -0.2) 0.04 
 SGRQ-C impact 15.5 (13.4) 17.6 (13.8) 17.5 (15.3) 19.9 (15.5) -0.9 (-2.9, 1.1) 0.4 
1Telephone PSM compared to usual care (negative values favour Telephone PSM). 
 
 
 
 
 
